Tirzepatide vs Semaglutide (2026): Which GLP-1 Is More Effective?

Semaglutide targets a single receptor: GLP-1. Tirzepatide targets two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

This dual-agonist mechanism is what sets tirzepatide apart. By activating both pathways simultaneously, tirzepatide provides enhanced appetite suppression, improved insulin sensitivity, and potentially greater metabolic benefits.

For a deeper dive into these mechanisms, see our article on how GLP-1 medications work. Think of semaglutide as a focused tool and tirzepatide as a broader one - both are effective, but they take different approaches.

The SURMOUNT trials for tirzepatide showed average weight loss of up to 22.5% of body weight at the highest dose over 72 weeks. The STEP trials for semaglutide (Wegovy) showed average weight loss of about 15% over 68 weeks.

While these numbers come from different trials and direct comparison requires caution, the trend is clear: tirzepatide has consistently shown greater weight loss in clinical research. Both medications significantly outperform older weight loss drugs and lifestyle intervention alone.

Both medications share similar gastrointestinal side effects - nausea, vomiting, diarrhea, and constipation are common, especially during dose escalation. In clinical trials, tirzepatide's side effect rates were broadly comparable to semaglutide's, with some studies suggesting slightly higher rates of certain GI symptoms at the highest tirzepatide doses.

The overall tolerability of both medications is considered acceptable, and side effects typically decrease over time. Read our semaglutide side effects guide for detailed management strategies that apply to both medications.

Brand-name versions of both medications are expensive - typically over $1,000 per month at retail price. Semaglutide has been available longer and has more compounded options through telehealth providers, which can significantly reduce cost.

Compounded tirzepatide is increasingly available but still less widespread. Insurance coverage varies for both and is often limited for weight loss indications.

For a complete pricing breakdown, see our medication cost guide.

Semaglutide (Wegovy) titrates from 0.25 mg to a maximum of 2.4 mg weekly over about 16 weeks. Tirzepatide (Mounjaro/Zepbound) starts at 2.5 mg and can go up to 15 mg weekly.

Both use gradual dose escalation to minimize side effects. The wider dosing range of tirzepatide gives providers more flexibility in finding the optimal dose.

For details on what the first month looks like, see our first month guide.

There's no universal answer. Tirzepatide may produce greater weight loss on average, which could be important for patients with more significant weight loss goals.

Semaglutide has a longer track record, more real-world data, and broader availability through telehealth providers. Some patients start with semaglutide and transition to tirzepatide if they hit a plateau, while others begin with tirzepatide based on their provider's recommendation.

The best choice depends on your health profile, weight loss goals, budget, and provider availability. Take our quiz to find a provider that offers the medication best suited to your needs.